全球HIV发病率分析及长效卡博特韦与连续和事件驱动口服暴露前预防的可负担性启示
该研究系统综述全球HIV发病率研究,纳入98项研究共5 230 189人,计算各高危人群加权发病率,并在10万人目标人群、每人每年18美元附加检测教育服务成本的假设下比较5种预防策略的年度HIV感染率与每预防1例感染的成本。结果显示当前价格的长效卡博特韦每预防1例HIV感染需949 487美元,而事件驱动口服替诺福韦/恩曲他滨仅需1923美元。作者认为长效卡博特韦高价限制固定预算内可治疗人数,低成本事件驱动口服方案在固定预算内预防感染最多。
要点
- 各人群发病率从献血者0.03/100人年到注射吸毒者3.82/100人年不等。
- 当前价格长效卡博特韦每预防1例HIV感染949 487美元,目标价格11 453美元,连续口服4231美元,事件驱动口服1923美元。
- 作者结论认为长效卡博特韦高价限制固定预算内可治疗人数,低成本事件驱动口服方案在固定预算内预防感染最多。
核心结论
- 当前价格的长效卡博特韦高价限制固定预算内可治疗人数,低成本事件驱动口服替诺福韦/恩曲他滨在固定预算内持续预防最多HIV感染。
研究设计与样本
- 系统综述全球HIV发病率研究,纳入98项研究共5 230 189人,计算各高危人群加权发病率。
- 以加权发病率和假设的10万人目标人群,评估5种预防策略的年度HIV感染率,每种策略附加每人每年18美元的检测、教育和服务可及成本。
- 假设效力为连续长效卡博特韦90%、连续口服替诺福韦/恩曲他滨60%、事件驱动口服替诺福韦/恩曲他滨60%。
主要发现
- 发病率每100人年从0.03(献血者)到3.82(注射吸毒者)不等。
- 在高危人群平均发病率2.6/100人年和10万人目标人群下,当前价格连续长效卡博特韦每预防1例HIV感染成本949 487美元,目标价格长效卡博特韦11 453美元,连续口服替诺福韦/恩曲他滨4231美元,事件驱动口服替诺福韦/恩曲他滨1923美元。
关键数值与推荐
- 预防策略假设效力:连续长效卡博特韦90%,连续口服替诺福韦/恩曲他滨60%,事件驱动口服替诺福韦/恩曲他滨60%。
- 每种策略附加检测、教育和服务可及成本为每人每年18美元。
- 高危人群平均发病率2.6/100人年,目标人群假设为10万人。
临床怎么用
- 作者认为在固定预防预算下,低成本事件驱动口服替诺福韦/恩曲他滨可持续预防最多HIV感染,而长效卡博特韦高价限制可治疗人数。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HIV Prevention Trials Network (HPTN) 083/084 trials showed up to 88% increased efficacy of long-acting cabotegravir (CAB-LA) versus continuous oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). However, CAB-LA's high price limits the number of people who can be treated within fixed prevention budgets. Global human immunodeficiency virus (HIV) prevention budgets are highly limited, with TDF/FTC widely available as a low-cost generic. In randomized clinical trials, event-driven TDF/FTC has shown similar preventive efficacy to continuous TDF/FTC. METHODS: A systematic review of global HIV incidence studies was conducted. Weighted incidence was calculated in each at-risk population. HIV infection rates were evaluated for 5 prevention strategies, with additional HIV testing, education, and service access costs assumed for each ($18 per person per year). Assumed efficacies were 90% (continuous CAB-LA), 60% (continuous TDF/FTC), and 60% (event-driven TDF/FTC). Using weighted incidence and an assumed 100 000 target population, annual HIV infection rates by population were calculated for each prevention strategy. RESULTS: Ninety-eight studies in 5 230 189 individuals were included. Incidence per 100 person-years ranged from 0.03 (blood donors) to 3.82 (people who inject drugs). Using the number needed to treat to benefit for each strategy, a mean incidence of 2.6 per 100 person-years in at-risk populations, and a 100 000 target population, current-price continuous CAB-LA cost $949 487 per HIV infection successfully prevented, followed by target-price CAB-LA ($11 453), continuous TDF/FTC ($4231), and event-driven TDF/FTC ($1923). CONCLUSIONS: High prices of CAB-LA limit numbers treatable within fixed budgets. Low-cost event-driven TDF/FTC consistently prevents the most HIV infections within fixed budgets.
引用
- Sharma I, Hill A. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. Clin Infect Dis. 2024. PMID: 37665213. doi:10.1093/cid/ciad537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。